chronic
infect
hepat
b
viru
hbv
global
health
concern
account
approxim
million
death
annual
amongst
limit
current
antihbv
treatment
failur
elimin
viral
coval
close
circular
dna
cccdna
emerg
resist
remain
worrisom
viral
rebound
latent
episom
cccdna
reservoir
occur
follow
cessat
therapi
patient
noncompli
develop
escap
mutant
simultan
viral
coinfect
complic
therapeut
intervent
challeng
prompt
develop
novel
target
hepat
b
therapi
given
eas
highli
specif
potent
nucleic
acid
therapeut
ration
design
gene
therapi
gener
interest
antivir
applic
gene
therapi
strategi
develop
hbv
includ
gene
silenc
har
rna
interfer
transcript
inhibit
epigenet
modif
target
dna
genom
edit
design
nucleas
immun
modul
cytokin
dnabind
domain
effector
base
zinc
finger
zf
transcript
activatorlik
effector
tale
cluster
regularli
interspac
short
palindrom
repeat
crispr
system
remark
well
suit
target
episom
cccdna
review
discuss
recent
develop
challeng
face
field
antihbv
gene
therapi
potenti
cur
signific
progress
toward
clinic
applic
viral
hepat
account
million
death
per
year
remain
major
caus
morbid
mortal
cirrhosi
hepatocellular
carcinoma
hepat
b
viru
hbv
infect
contribut
significantli
global
health
problem
estim
million
peopl
chronic
infect
major
health
prioriti
year
pass
sinc
discoveri
australia
antigen
valuabl
progress
made
vaccin
antivir
develop
still
reliabl
cure
hbv
infect
worldwid
prophylact
vaccin
program
reduc
preval
hbv
children
age
five
inadequ
coverag
hyperendem
african
countri
mean
preval
remain
high
countri
manag
chronic
hbv
infect
involv
use
immun
modul
directact
antivir
form
interferon
nucleosidenucleotid
analog
na
rational
combin
therapi
manag
immun
dysregul
well
viral
pathogenesi
current
approv
therapeut
includ
interferon
pegyl
interferon
lamivudin
telbivudin
adenovir
dipivoxil
entecavir
tenofovir
disoproxil
fumar
tenofovir
alafenamid
recommend
firstlin
monotherapi
pegyl
interferon
na
high
barrier
resist
entecavir
tenofovir
disoproxil
fumar
tenofovir
alafenamid
guidelin
administr
combin
therapi
sometim
vari
result
conflict
opinion
longterm
efficaci
influenc
patient
select
whether
simultan
sequenti
administr
favor
review
critic
limit
licens
therapeut
inabl
reliabl
achiev
virolog
cure
na
inhibit
posttranscript
stage
viral
replic
target
stabl
episom
coval
close
circular
dna
cccdna
key
hbv
replic
intermedi
form
minichromosom
nucleu
hepatocyt
may
undergo
epigenet
modif
hepat
b
x
protein
hbx
play
role
stabil
cccdna
inactiv
compon
structur
mainten
chromosom
smc
complex
cccdna
associ
host
transcript
factor
viral
protein
enabl
viral
gene
express
replic
associ
factor
regul
methyl
heterochromatin
format
may
also
render
cccdna
inact
lead
persist
latent
occult
hbv
infect
cessat
interrupt
antivir
therapi
develop
viral
escap
mutant
immunodefici
could
lead
reactiv
hbv
replic
highlight
need
cccdnaspecif
therapi
review
focus
recent
advanc
aim
gener
hbvtarget
design
nucleas
epigenet
modif
viral
dna
nucleic
acidbas
immun
modul
treat
chronic
hbv
infect
sever
novel
antihbv
therapeut
preclin
develop
earli
clinic
trial
review
candid
drug
small
molecul
drug
design
imped
variou
stage
hbv
replic
afford
nextgener
na
inhibit
viral
polymeras
reduc
toxic
higher
barrier
hbv
resist
current
prefer
firstlin
therapi
directact
antivir
includ
hbv
core
protein
alloster
modul
hbv
surfac
antigen
hbsag
releas
inhibitor
nucleic
acid
polym
also
inhibit
viral
entri
discoveri
sodium
taurochol
cotransport
polypeptid
ntcp
facilit
hbv
entri
hepatocyt
peptid
inhibitor
myrcludexb
also
develop
therapeut
applic
anoth
popular
hostrel
strategi
recondit
immun
system
use
interferon
cytokin
peptid
immun
modul
discuss
detail
section
use
gene
therapi
disabl
hbv
replic
shown
promis
gener
consider
interest
differ
strategi
employ
includ
hbvspecif
gene
silenc
gene
edit
epigenom
modif
nucleic
acidbas
vaccin
har
rna
interfer
rnai
pathway
wellestablish
strategi
use
extens
silenc
gene
hbv
rnai
endogen
gene
regulatori
pathway
reprogram
exogen
rna
molecul
feasibl
use
rnai
treat
hbv
establish
extens
review
elsewher
cover
detail
express
synthet
antivir
sequenc
may
mimic
primari
microrna
precursor
microrna
matur
microrna
mir
easier
largescal
product
dose
control
deliveri
cytoplasm
site
action
develop
synthet
short
interf
rna
sirna
advanc
rapidli
simul
matur
mir
phase
clinic
trial
antihbv
sirna
formul
impress
antivir
activ
includ
alnhbv
howev
sinc
effect
transient
repeat
administr
sirna
requir
long
term
antihbv
efficaci
increas
durabl
antihbv
effect
express
hbvtarget
sequenc
develop
exampl
adenoassoci
viral
vector
aav
use
deliv
cassett
express
hbvtarget
primari
microrna
mimic
safe
sustain
inhibit
hbv
replic
hbv
transgen
mice
indic
approach
potenti
clinic
translat
strategi
target
host
factor
also
shown
signific
promis
reduc
cccdna
level
rnaimedi
gene
silenc
tyrosyldnaphosphodiesteras
dna
repair
enzym
thought
mediat
polymeras
releas
relax
circular
dna
delay
convers
cccdna
cell
recent
studi
also
demonstr
silenc
express
premrna
process
factor
hbxinteract
partner
reduc
cccdna
level
cell
hbv
therapeut
landscap
vast
approach
develop
disabl
cccdna
directli
target
mutagenesi
sequencespecif
rnaguid
nucleas
rgn
protein
thu
gener
consider
interest
technolog
potenti
provid
mean
cure
hbv
infect
perman
disabl
cccdna
design
nucleas
domin
antihbv
gene
edit
field
zinc
finger
nucleas
zfn
transcript
activatorlik
effector
nucleas
talen
cluster
regularli
interspac
short
palindrom
repeat
crispr
crisprassoci
ca
system
show
antivir
efficaci
tabl
nucleas
act
induc
doubl
strand
break
predefin
target
site
within
hbv
genom
figur
exploit
host
cell
errorpron
nonhomolog
end
join
repair
machineri
target
mutagenesi
realiz
hbv
cccdna
primari
candid
nucleas
gene
edit
owe
episom
minichromosom
configur
limit
sequenc
plastic
compact
viral
genom
overlap
read
frame
restrict
develop
escap
mutant
despit
low
fidel
viral
revers
transcriptas
insert
delet
indel
within
viral
genom
may
give
rise
aberr
truncat
protein
turn
interfer
viral
replic
zinc
finger
zf
abund
multifunct
mammalian
protein
occur
natur
transcript
factor
exploit
specif
target
nucleotid
triplet
singl
zf
protein
may
engin
form
array
defin
dna
bind
properti
addit
foki
effector
domain
cterminu
zf
yield
engin
nucleas
cut
one
strand
dna
duplex
zfn
dimer
cognat
complementari
strand
dna
duplex
may
thu
use
creat
doubl
strand
break
antihbv
zfn
first
describ
proofofconcept
experi
plasmidderiv
viral
sequenc
disrupt
cell
cultur
model
viral
replic
recent
weber
et
al
report
deliveri
selfcomplementari
adenoassoci
viral
vector
scaav
encod
zfn
target
polymerasex
polymerasecor
polymeras
viral
open
read
frame
orf
use
induc
liverderiv
cell
mimic
natur
hbv
infect
zfn
pair
cleav
viral
target
respect
result
confirm
use
singl
molecul
real
time
sequenc
addit
identifi
potenti
target
albeit
low
frequenc
interestingli
zfn
pair
result
highest
detect
target
disrupt
yet
also
found
cytotox
zfn
pair
show
antivir
efficaci
cleavag
cccdna
could
verifi
zfn
talen
dimer
engin
nucleas
compris
dnabind
protein
fuse
endonucleas
domain
transcript
activatorlik
effector
tale
deriv
xanthomona
bacteria
individu
repeat
domain
compris
amino
acid
recogn
singl
base
pair
nucleotid
bind
specif
repeat
predetermin
repeatvari
diresidu
rvd
locat
amino
acid
posit
link
multipl
repeat
defin
order
gener
engin
tale
highli
specif
dna
bind
properti
unlik
zfn
nucleotid
bind
affin
monom
compris
dna
bind
domain
influenc
neighbor
unit
group
first
describ
antivir
efficaci
engin
talen
hbv
cccdna
cultur
cell
inhibit
viral
replic
murin
model
talen
dimer
design
bind
within
surfac
core
c
orf
show
optim
cleavag
activ
cell
line
without
measur
cytotox
importantli
cccdna
target
disrupt
frequenc
achiev
c
talen
pair
respect
use
murin
hydrodynam
inject
hdi
model
coadministr
hbv
replicationcompet
plasmid
talenencod
sequenc
demonstr
vivo
antivir
efficaci
nucleas
evid
liver
toxic
signific
substanti
reduct
serum
concentr
hbsag
circul
viral
particl
equival
observ
talentr
mice
target
mutagenesi
achiev
deep
sequenc
verifi
larg
delet
viral
dna
like
inactiv
hbv
replic
subsequ
studi
chen
et
al
confirm
cccdnaspecif
antivir
potenti
talen
design
target
conserv
region
within
polymeras
rnaseh
sequenc
c
orf
achiev
liverderiv
cell
transfect
linear
viral
sequenc
gener
cccdna
recapitul
hbv
replic
reduct
viral
protein
express
observ
across
genotyp
b
c
emphas
applic
antihbv
talen
varieti
viral
isol
moreov
synergist
effect
shown
combin
core
talen
result
approxim
reduct
copi
cccdna
anoth
studi
cotransfect
linear
donor
sequenc
encod
trimer
gene
silenc
significantli
augment
antihbv
efficaci
c
talen
pair
cell
approach
exploit
homolog
direct
repair
pathway
introduc
artifici
primari
micrornaencod
sequenc
directli
viral
dna
viral
genom
may
perman
disrupt
homolog
recombin
hbv
dna
transcrib
antivir
sequenc
rearrang
genom
use
rgn
popular
method
inactiv
hbv
gene
express
bacteri
system
reli
rna
guid
dna
bind
domain
associ
endonucleas
rgn
typic
compris
crispr
rna
crrna
sequenc
complementari
predefin
dna
target
sequenc
transactiv
crrna
tracrrna
anneal
rna
cognat
enabl
doublestrand
target
dna
cleavag
fuse
crrna
tracrrna
form
singl
guid
rna
grna
simplifi
system
made
rgn
easiest
nucleas
engin
sinc
first
report
lin
et
al
public
describ
antihbv
efficaci
rgn
tabl
target
mutagenesi
cccdna
mammalian
cell
cultur
first
demonstr
seeger
sohn
design
construct
bind
conserv
enhanc
iicor
promot
precor
orf
subsequ
studi
confirm
singl
multipl
grna
span
entir
hbv
genom
cleav
cccdna
caus
indel
format
result
reduc
viral
protein
express
howev
method
use
detect
mutagen
event
vari
greatli
individu
studi
make
difficult
compar
effici
differ
grna
construct
directli
nevertheless
design
nucleas
target
conserv
region
advantag
antivir
efficaci
achiev
across
differ
genotyp
second
studi
seeger
sohn
use
next
gener
sequenc
map
cccdna
mutat
major
indel
identifi
small
delet
extrem
high
target
cleavag
achiev
although
offtarget
cleavag
may
frequent
associ
action
data
potenti
hbv
rgn
creat
nonspecif
mutat
scarc
use
multipl
grna
improv
antivir
efficaci
excis
integr
viral
dna
fragment
figur
may
exacerb
issu
expect
offtarget
cleavag
event
detect
deep
sequenc
multipl
grna
use
howev
studi
report
detect
genotox
activ
may
result
differ
grna
design
properti
viral
target
sequenc
replac
endonucleas
engin
nickas
may
improv
specif
hbv
rgn
configur
grna
nickas
compris
heterodim
requir
effect
doubl
strand
dna
cleavag
anoth
challeng
system
relat
deliveri
combin
grna
larg
endonucleas
sequenc
encod
two
compon
exceed
transgen
capac
popular
aav
recent
public
scott
et
al
demonstr
smaller
deriv
staphylococcu
aureu
sa
togeth
express
cassett
encod
short
grna
target
hbv
surfac
orf
could
packag
singl
strand
aav
ssaav
effici
deliveri
express
rgnencod
ssaav
cell
result
decreas
viral
replic
target
specif
cccdna
cleavag
reduc
cccdna
copi
number
analysi
sequenc
predict
target
site
reveal
nonspecif
mutagenesi
natur
epigenet
modif
dna
may
silenc
gene
express
host
defenc
mechan
express
viral
gene
epigenet
modif
stabl
herit
gene
regulatori
mechan
found
mani
differ
organ
involv
chemic
alter
dna
associ
protein
without
chang
encod
genet
inform
involv
typic
cell
develop
multipl
normal
abnorm
cellular
respons
review
accumul
evid
indic
epigenet
machineri
control
transcript
hbv
cccdna
figur
contribut
outcom
chronic
hbv
infect
use
exogen
epigenet
modifi
thu
attract
interest
mode
disabl
cccdna
epigenet
modif
includ
histon
acetyl
deacetyl
histon
methyl
demethyl
cccdna
methyl
cccdna
minichromosom
acetyl
review
cooper
viral
factor
hbx
core
antigen
hbc
major
epigenet
modifi
hbv
dna
includ
histon
acetyltransferasesdeacetylas
hatshdac
lysin
methyltransferas
protein
arginin
methyltransferas
dna
methyltransferas
dnmt
hypoacetyl
cccdnabound
histon
result
low
hbv
viremia
hepat
b
patient
wherea
hyperacetyl
increas
hbv
replic
hdac
inhibitor
shown
suppress
cccdna
transcript
duck
hepat
b
viru
dhbv
methyl
arginin
cccdnabound
histon
prevent
rna
polymeras
bind
transcript
arginin
methyltransferas
hbcdepend
manner
transcript
inhibit
methyl
direct
block
bind
transcript
factor
rnapolymeras
load
well
indirect
recruit
histonemodifi
chromatin
remodel
complex
methyl
dna
review
epigenet
gene
silenc
may
facilit
reduct
viral
reservoir
normal
hepatocyt
turnov
prevent
replenish
cccdna
pool
furthermor
epigenet
modif
may
acceler
cccdna
decay
shown
follow
treatment
dhbv
infect
hbv
cccdna
contain
three
cpg
island
island
island
ii
island
iii
island
overlap
start
site
gene
island
ii
encompass
enhanc
hbx
gene
promot
core
promot
wherea
island
iii
harbor
promot
start
codon
polymeras
gene
methyl
island
rare
variabl
across
genotyp
wherea
methyl
island
ii
iii
conserv
island
iii
methyl
associ
reduc
serum
hbsag
concentr
chronic
infect
patient
correl
hepatocarcinogenesi
island
ii
methyl
associ
reduc
pregenom
rna
pgrna
transcript
viral
replic
viremia
vitro
studi
show
sever
dnmt
upregul
respons
hbv
infect
lead
viral
dna
methyl
decreas
hbv
gene
express
diminish
viral
replic
importantli
similar
reduct
viral
gene
express
viremia
observ
human
tissu
sampl
methyl
hbv
dna
despit
import
hbv
dna
epigenet
modif
diseas
progress
evid
support
feasibl
use
epigenet
modifi
hbv
current
limit
studi
taken
advantag
sequencespecif
bind
domain
design
nucleas
repurpos
epigenet
silenc
replac
nucleas
domain
design
nucleas
epigenet
modul
zf
tale
crisprca
usual
modifi
epigenet
edit
endogen
gene
review
howev
strategi
theoret
applic
target
epigenet
modif
hbv
dna
one
studi
report
success
epigenet
edit
hbv
dna
fuse
catalyt
domain
zf
target
hbx
promot
sequenc
engin
sequenc
caus
methyl
target
cpg
site
downregul
viral
mrna
protein
decreas
viral
replic
cell
cultur
hbv
transgen
mice
repressor
base
associ
box
krab
domain
also
investig
zf
tale
fusion
although
krabrepressor
inhibit
viral
replic
verif
heterochromatin
format
import
achiev
perman
gene
silenc
remain
confirm
studi
demonstr
antivir
efficaci
sustain
epigenet
editor
hbv
replic
preliminari
howev
investig
aim
develop
approach
treat
chronic
viral
infect
hiv
advanc
moreov
food
drug
administr
fda
approv
hdac
inhibitor
cancer
treatment
support
notion
epigenet
edit
clinic
potenti
treatment
hbv
infect
administr
recombin
pegyl
deriv
remain
immunomodulatori
drug
licens
manag
chronic
hbv
infect
therefor
licens
antihbv
therapi
capabl
elimin
cccdna
immunomodul
shown
augment
innat
adapt
immun
respons
viru
stimul
tcellmedi
elimin
infect
hepatocyt
indirectli
cccdna
thu
promis
immunebas
strategi
achiev
function
cure
hbv
infect
howev
success
rate
ifn
therapi
remain
low
side
effect
repres
major
shortcom
therapi
gene
therapi
enabl
durabl
express
immun
modul
may
use
attenu
cccdna
express
sequenc
liver
explor
mean
improv
antihbv
efficaci
reduc
side
effect
convent
treatment
one
first
studi
explor
express
murin
transcript
control
liverspecif
transthyretin
promot
express
construct
deliv
liver
mice
use
helperdepend
adenoviru
hdad
interferon
respons
gene
oligoadenyl
synthetas
tumor
necrosi
factor
effect
induc
surrog
assess
antihbv
potenti
system
author
challeng
mice
murin
coronaviru
mice
pretreat
hdad
carri
protect
infect
exhibit
toxic
side
effect
fiedler
et
al
assess
use
gene
therapybas
approach
express
woodchuck
hepat
viru
whv
model
hbv
infect
sequenc
encod
woodchuck
deliv
woodchuck
hdad
anim
chronic
infect
whv
viral
replic
intermedi
liver
serum
consider
diminish
signific
find
whv
maintain
high
viral
load
host
much
higher
chronic
hbv
carrier
furthermor
obviou
side
effect
observ
express
last
least
year
contrast
promis
result
achiev
express
signific
effect
whv
replic
differ
result
dumorti
et
al
demonstr
express
abl
limit
hbv
replic
mice
subsequ
work
assess
util
aav
vector
deliveri
interferon
express
cassett
berraondo
et
al
test
intrahepat
intramuscular
express
follow
administr
woodchuck
chronic
infect
whv
interferon
readili
express
site
deliveri
express
liver
superior
furthermor
express
interferon
liver
associ
antivir
respons
although
higher
vector
dose
pronounc
antivir
effect
also
associ
greater
toxic
woodchuck
greatest
decreas
viremia
exhibit
sever
side
effect
requir
euthanasia
prior
complet
studi
anoth
limit
approach
transient
natur
antivir
effect
attribut
immunemedi
clearanc
aavinfect
hepatocyt
improv
deliveri
system
berraondo
et
al
develop
modifi
fuse
sequenc
encod
apolipoprotein
interapo
initi
assess
demonstr
interapo
exhibit
improv
safeti
profil
maintain
antivir
efficaci
hbv
transgen
mice
woodchuck
chronic
infect
whv
aavdeliv
interapo
welltoler
show
littl
efficaci
attribut
high
whv
load
woodchuck
chronic
hepat
pretreat
woodchuck
na
entecavir
subsequ
administr
aavinterapo
facilit
immunemedi
clearanc
howev
antivir
effect
transient
viral
rebound
pretreat
level
eventu
occur
evalu
gene
therapybas
immun
modul
explor
antivir
effect
sequenc
encod
interleukin
crettaz
et
al
assess
efficaci
hdaddeliv
whv
model
author
use
murin
sequenc
transcript
control
induc
promot
deliv
cassett
directli
liver
viral
vector
interestingli
woodchuck
viral
load
lower
viral
genom
equival
per
ml
serum
respond
well
treatment
wherea
higher
viral
load
extens
character
reveal
decreas
intrahepat
viral
dna
rna
level
liver
inflamm
reduc
woodchuck
hepat
e
surfac
antigen
clear
serum
significantli
disappear
intrahepat
core
antigen
attribut
tcell
respons
viru
induc
importantli
treatment
shown
welltoler
group
subsequ
evalu
efficaci
express
semliki
forest
viru
vector
aim
assess
antitumor
effect
construct
whvinduc
hcc
author
also
show
strong
antivir
respons
result
intrahepat
express
antitumor
antivir
effect
attribut
induct
tcell
respons
potenti
use
cytokin
treat
hbv
infect
highlight
recent
studi
evalu
efficaci
dual
express
counter
hbv
replic
transgen
mice
coadministr
aav
encod
gene
aav
carri
sequenc
result
near
complet
clearanc
intrahepat
hbc
viral
dna
replic
intermedi
importantli
express
shown
induc
antibodi
respons
function
antivir
tcell
respons
author
assess
combin
strategi
use
recombin
sampl
patient
chronic
hbv
infect
stimul
peripher
blood
mononuclear
cell
patient
hbc
peptid
presenc
effector
function
restor
hbv
specif
tcell
reconstitut
cytotox
tcell
respons
hbv
hold
great
promis
strategi
immunemedi
clearanc
viru
chronic
carrier
engin
tcell
chimer
tcell
receptor
hbv
antigen
develop
investig
yet
progress
beyond
preclin
develop
technolog
dna
vaccin
potenti
induc
strong
antibodi
tcellmedi
immun
respons
therebi
clear
chronic
hbv
infect
review
studi
explor
strategi
induc
strong
antivir
immun
therapeut
vaccin
conjunct
cytokinemedi
stimul
immun
respons
undoubtedli
potenti
manag
chronic
hepat
b
realiz
function
complet
cure
chronic
hbv
infect
requir
innov
therapeut
approach
aim
disabl
elimin
persist
episom
cccdna
drug
act
directli
viral
genom
design
nucleas
epigenet
modifi
potenti
disabl
viral
replic
perman
restor
antihbv
immun
respons
may
also
facilit
clearanc
infect
hepatocyt
thu
diminish
erad
cccdna
pool
combin
genebas
immun
cccdnatarget
gene
therapi
may
provid
mean
achiev
goal
challeng
broadli
associ
implement
genebas
therapi
also
need
met
approach
success
hbv
effici
liverspecif
deliveri
use
viral
nonvir
vector
still
remain
challeng
particularli
import
multipl
dose
gene
therapi
requir
improv
dnabind
specif
particularli
design
nucleas
defin
target
effect
vital
limit
unintend
side
effect
lack
suitabl
chronic
hbv
infect
model
also
complic
develop
gene
therapi
treatment
diseas
system
shown
target
cccdna
effici
primari
duck
hepatocyt
infect
dhbv
although
dhbv
infect
duck
provid
use
model
chronic
hbv
infect
recapitul
aspect
condit
human
despit
challeng
face
clinic
translat
genebas
cur
therapi
chronic
hbv
infect
field
gain
momentum
signific
progress
seem
immin
